Tanaka Yasushi, Oki Eiji, Nakanishi Ryota, Kawazoe Tetsuro, Kudo Kensuke, Zaitsu Yoko, Hisamatsu Yuichi, Ando Koji, Oda Yoshinao, Yoshizumi Tomoharu
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Cancer Sci. 2025 Jul;116(7):2032-2039. doi: 10.1111/cas.70088. Epub 2025 May 3.
Polo-like kinase 1 (PLK1) controls mitotic spindle formation and cytokinesis. However, its role as a predictive biomarker for treatment outcomes in colorectal cancer (CRC) remains underexplored, particularly in the context of RAS mutations. We retrospectively analyzed the relationships among PLK1 expression, clinicopathological factors, and survival in 225 patients who underwent CRC surgery. We also analyzed the relationship between PLK1 expression and survival after adjuvant chemotherapy and how RAS mutation influenced the prognosis. We found that PLK1 expression was significantly correlated with histopathology (p < 0.0001) and perineural invasion (p = 0.005). The high PLK1 expression group tended to have a worse prognosis in terms of relapse-free survival than the low expression group for all patients (p = 0.060) and patients with stage III disease (p = 0.055). In patients who received adjuvant chemotherapy for stage III CRC, high PLK1 expression was the only poor prognostic factor for relapse-free survival (p = 0.01), and those with mutated RAS had a significantly poorer prognosis than those with wild-type RAS (p = 0.027). In patients with CRC, high PLK1 expression was associated with poor survival after adjuvant chemotherapy, and there was potential involvement of the RAS mutation.
Polo样激酶1（PLK1）控制有丝分裂纺锤体的形成和胞质分裂。然而，其作为结直肠癌（CRC）治疗结果预测生物标志物的作用仍未得到充分探索，尤其是在RAS突变的背景下。我们回顾性分析了225例行CRC手术患者的PLK1表达、临床病理因素与生存之间的关系。我们还分析了PLK1表达与辅助化疗后生存的关系以及RAS突变如何影响预后。我们发现PLK1表达与组织病理学（p＜0.0001）和神经周围浸润（p = 0.005）显著相关。在所有患者（p = 0.060）和III期疾病患者（p = 0.055）中，高PLK1表达组的无复发生存预后往往比低表达组更差。在接受III期CRC辅助化疗的患者中，高PLK1表达是无复发生存的唯一不良预后因素（p = 0.01），且RAS突变患者的预后明显比野生型RAS患者差（p = 0.027）。在CRC患者中，高PLK1表达与辅助化疗后的不良生存相关，且可能存在RAS突变的影响。
